Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 129764, 6 pages
Research Article

Copper-64 Dichloride as Theranostic Agent for Glioblastoma Multiforme: A Preclinical Study

1Nuclear Medicine, University “Aldo Moro”, Piazza Giulio Cesare 11, 70124 Bari, Italy
2Nuclear Medicine, Hospital “Spirito Santo”, Pescara, Italy
3Advanced Center Oncology Macerata (ACOM) S.p.A., Montecosaro, Italy

Received 3 September 2015; Accepted 22 October 2015

Academic Editor: Bianca Gutfilen

Copyright © 2015 Cristina Ferrari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults with a median survival time less than one year. To date, there are only a limited number of effective agents available for GBM therapy and this does not seem to add much survival advantage over the conventional approach based on surgery and radiotherapy. Therefore, the development of novel therapeutic approaches to GBM is essential and those based on radionuclide therapy could be of significant clinical impact. Experimental evidence has clearly demonstrated that cancer cells have a particularly high fractional content of copper inside the nucleus compared to normal cells. This behavior can be conveniently exploited both for diagnosis and for delivering therapeutic payloads (theranostic) of the radionuclide copper-64 into the nucleus of cancerous cells by intravenous administration of its simplest chemical form as dichloride salt [64Cu]CuCl2. To evaluate the potential theranostic role of [64Cu]CuCl2 in GBM, the present work reports results from a preclinical study carried out in a xenografted GBM tumor mouse model. Biodistribution data of this new agent were collected using a small-animal PET tomograph. Subsequently, groups of tumor implanted nude mice were treated with [64Cu]CuCl2 to simulate single- and multiple-dose therapy protocols, and results were analyzed to estimate therapeutic efficacy.